use only
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and ASX | |||
Name of listed issuer: | Oceania Healthcare Limited | ||
Date this disclosure made: | 31 | May 2022 | |
Date of last disclosure: | 23 | December 2021 | |
Director or senior manager giving disclosure | |||
Full name(s): | Elizabeth Coutts | ||
Name of listed issuer: | Oceania Healthcare Limited | ||
Name of related body corporate (if applicable): | N/A | ||
Position held in listed issuer: | Director | ||
Summary of acquisition or disposal of relevant interest (excluding derivatives)
personal
Class of affected quoted financial products:
Nature of the affected relevant interest(s):
For that relevant interest -
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:
Ordinary shares
Beneficial owner of shares
1,644,692
1,694,692
Unknown
Custodial Services Limited
For
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: | N/A | |
Class of underlying financial products: | N/A | |
Details of affected derivative - | ||
The notional value of the derivative (if any) or the notional | N/A | |
amount of underlying financial products (if any): | ||
A statement as to whether the derivative is cash settled or | N/A | |
physically settled: | ||
Maturity date of the derivative (if any): | N/A | |
Expiry date of the derivative (if any): | N/A | |
The price specified in the terms of the derivative (if any): | N/A | |
Any other details needed to understand how the amount of | N/A | |
the consideration payable under the derivative or the value |
only
of the derivative is affected by the value of the underlying financial products:
For that derivative: - | ||
Parties to the derivative: | N/A | |
If the director or senior manager is not a party to the | N/A | |
derivative, the nature of the relevant interest in the | ||
derivative: | ||
Details of transactions giving rise to acquisition or disposal | ||
Total number of transactions to which notice relates: | 1 | |
Details of transactions requiring disclosure - |
personal use
Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):
27 May 2022
On market acquisition
$50,500.00
50,000
No
N/A
N/A
For
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: | N/A | |
Nature of relevant interest: | N/A | |
For that relevant interest - | ||
Number held in class: | N/A | |
Current registered holder(s): | N/A | |
For a derivative relevant interest - | ||
Type of derivative: | N/A | |
Details of derivative - | ||
The notional value of the derivative (if any) or the notional | N/A | |
amount of underlying financial products (if any): | ||
A statement as to whether the derivative is cash settled or | N/A | |
physically settled: | ||
For personal use only
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
N/A
N/A
N/A
N/A
N/A
N/A
31 May 2022
Anna Thorburn
Group General Manager
Corporate Services
use only
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and ASX | |||
Name of listed issuer: | Oceania Healthcare Limited | ||
Date this disclosure made: | 31 | May 2022 | |
Date of last disclosure: | 23 | December 2021 | |
Director or senior manager giving disclosure | |||
Full name(s): | Sally Evans | ||
Name of listed issuer: | Oceania Healthcare Limited | ||
Name of related body corporate (if applicable): | N/A | ||
Position held in listed issuer: | Director | ||
Summary of acquisition or disposal of relevant interest (excluding derivatives)
personal
Class of affected quoted financial products:
Nature of the affected relevant interest(s):
For that relevant interest -
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:
Ordinary shares
Registered and beneficial owner of shares
98,025
138,025
Unknown
Sally Evans
For
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: | N/A | |
Class of underlying financial products: | N/A | |
Details of affected derivative - | ||
The notional value of the derivative (if any) or the notional | N/A | |
amount of underlying financial products (if any): | ||
A statement as to whether the derivative is cash settled or | N/A | |
physically settled: | ||
Maturity date of the derivative (if any): | N/A | |
Expiry date of the derivative (if any): | N/A | |
The price specified in the terms of the derivative (if any): | N/A | |
only
Any other details needed to understand how the amount of | N/A | |
the consideration payable under the derivative or the value | ||
of the derivative is affected by the value of the underlying | ||
financial products: | ||
For that derivative: - | ||
Parties to the derivative: | N/A | |
If the director or senior manager is not a party to the | N/A | |
derivative, the nature of the relevant interest in the | ||
derivative: | ||
Details of transactions giving rise to acquisition or disposal | ||
Total number of transactions to which notice relates: | 1 | |
Details of transactions requiring disclosure - |
personal use
Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):
24 May 2022
On market acquisition of shares
$42,000.00
40,000
No
N/A
N/A
For
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: | N/A | |
Nature of relevant interest: | N/A | |
For that relevant interest - | ||
Number held in class: | N/A | |
Current registered holder(s): | N/A | |
For a derivative relevant interest - | ||
Type of derivative: | N/A | |
Details of derivative - | ||
The notional value of the derivative (if any) or the notional | N/A | |
amount of underlying financial products (if any): | ||
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Oceania Healthcare Ltd. published this content on 30 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 May 2022 22:49:02 UTC.